Trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir

Journal of Clinical Pharmacology

Volumn 39, Issue 10, 1999, Pages 1077-1084

  Sturgill, M G ^a   Seibold, J R ^a   Boruchoff, S E ^a   Yeh, K C ^a   Haddix, H ^a   Deutsch, P ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; INDINAVIR; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0033321531     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922011737     Document Type: Article

References (29)

1. Protease inhibitor approved for AIDS treatment
2. Role of human immunodeficiency virus type 1-specific protease in core maturation and viral infectivity
3. Advances in antiretroviral therapy and viral load monitoring
4. An Orally bioavailable human immunodeficiency virus type 1 protease inhibitor
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
7. Disposition of indinavir sulfate, a potent HIV-1 protease inhibitor, after an oral dose in humans
8. Pharmacokinetics of trimethoprim and its combination with sulfamethoxazole in man after single and chronic oral administration
9. Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses
10. Drug interactions involving renal transport mechanisms: An overview
11. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole
12. Trimethoprim, alone or in combination with sulfamethoxazole, decreases the renal excretion of zidovudine and its glucuronide
13. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia
14. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes
15. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
16. The effect of different sulfonamides on phenytoin metabolism in man
17. Cotrimoxazole as an inhibitor of oxidative drug metabolism: Effects of trimethoprim and sulfamethoxazole separately and combined on tolbutamide disposition
18. The effect of cotrimoxazole on oral contraceptive steroids in women
19. 3
20. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective, noncrossover study
21. Pharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjects
22. Determination of L-735,524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching
23. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions
24. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients
25. Species differences in the pharmacokinetics and metabolism of indinavir sulfate, a potent human immunodeficiency virus protease inhibitor
26. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine
27. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor
28. HIV-1 protease inhibitors: A review for clinicians